Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

A person's 'bioenergetic age' -- or how youthfully their cells generate energy -- might be a key indicator of whether they're at risk of developing Alzheimer's disease, new research shows. The study ...

A person’s “bioenergetic age”, or how youthfully their cells generate energy, might be a key indicator of whether they’re at ...

However, in some cases, both treatments have been associated with minimal clinical relevance in slowing dementia progression. Both lecanemab and donanemab are costly treatments that may increase ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly ...

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia TOKY ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

for an average patient with very mild symptoms due to Alzheimer disease dementia, treatment with either lecanemab or donanemab would be expected to extend independent living for around one year ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...